BIOGENERA SpA has officially signed an agreement with CVBF (Consortium for Biological and Pharmacological Evaluations) to monitor and execute the phase I clinical trial of the new drug BGA002, intended for the treatment of aggressive pediatric cancers associated with alterations in the MYCN tumor gene. BIOGENERA has chosen CVBF as its Clinical CRO (Contract Research […]
Category: Corporate Update
Corporate Update
Funding from European Community approved for collaborative research program between BIOGENERA SpA and University of Padua
Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua. The research program aims to develop a new, unique […]
Corporate Update
New operating unit of BIOGENERA SpA in Paris in the prestigious Paris Saclay Cancer Cluster (PSCC)
BIOGENERA SpA is in the process of finalizing the establishment of a new operating unit of the Company in Paris. After a period of careful evaluation for the most appropriate choice, the final decision was made for the Paris Saclay Cancer Cluster (PSCC)(https://www.parissaclaycancercluster.org). The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif […]
Corporate Update
A New Goal for Biogenera: BGA002, the Future of Cancer Therapy
The Biogenera team has achieved a major breakthrough in the development of the innovative anti-tumor drug BGA002: a revolutionary drug that targets aggressive tumors in both children and adults, specifically targeting cancer cells and sparing healthy ones. An Innovation in the Fight Against Cancer. New scientific data show that BGA002 is able to penetrate and […]
Corporate Update
NewCap is chosen as the new investor relations firm for BIOGENERA
News Body: An agreement has been signed with NewCap, a French Investor Relation company, which will be in charge of managing BIOGENERA SpA’s official communications as of its listing on Euronext Paris. NewCap was selected because it has extensive experience in Investor Relations (IR) of companies listed on the Paris Euronext exchange, including companies in […]
Corporate Update
Thibaud Eckenschwiller has been appointed president of BIOGENERA, May 2023
On May 2, 2023, BIOGENERA’s shareholders’ meeting approved the 2022 budget; the new Board of Directors (BOD) was also appointed on this occasion. Dr. Thibaud Eckenschwiller has been appointed chairman of the board of BIOGENERA. Dr. Eckenschwiller is a top manager in the pharmaceutical industry with extensive international experience. Dr. Eckenschwiller is Senior Life Sciences […]
Corporate Update
Giacinto d’Ettorre becomes board member of BIOGENERA
Dr. Giacinto d’Ettorre has been appointed as a new board member of BIOGENERA. Dr. D’Ettorre has many years of experience in the pharmaceutical industry at management levels. He currently serves as chief financial officer (CFO) at a leading pharmaceutical company, and previously served as CFO of Europe at SHIRE (now merged into TAKEDA), and CFO […]
Corporate Update
The company ComputerShare has been chosen to manage the corporate structure of BIOGENERA.
BIOGENERA has signed an agreement with Computershare Italia, which is part of Computershare Limited, the leading stock transfer company that provides corporate trust, stock transfer and employee stock plan services in numerous countries. Computershare will mainly deal with the dematerialization of shares at MonteTitoli and other activities related to the management of shares since the […]
Corporate Update
Mario Nespoli is the new CFO of BIOGENERA
BIOGENERA has appointed as the company’s new chief financial officer (CFO) Dr. Mario Nespoli, who has many years of experience in the pharmaceutical industry at management levels. Dr. Nespoli served as general manager for REYS Spa, where he created a new management team, opened new branches in the European Union, and invested in new production […]
Corporate Update
INTEGRAE SIM is chosen as Listing Sponsor and Global Coordinator.
BIOGENERA has chosen INTEGRAE SIM (a leading Italian company in extraordinary finance for SMEs with more than 60 successfully completed IPOs) as Listing Sponsor and Global Coordinator for the path of preparing the IPO on Euronext Paris. INTEGRAE SIM develops a wide range of investment banking services focused mainly on small- and mid-capitalization companies to […]
Corporate Update
BIOGENERA closes at more than 2.8 million raised on CrowdFundMe
BIOGENERA SpA’s crowdfunding campaign conducted on the CrowdFundMe digital platform, which ended in October 2021, recorded an average investment of about 4,400 euros, thus totaling for BIOGENERA a collection of more than 2.8 million euros from 644 investors. campaign link: equity crowdfunding campaign conducted on CrowdFundMe The more than 2.8 million euros raised in less […]
Corporate Update
BIOGENERA chooses Gitti & Partners as legal advisor
BIOGENERA SpA has chosen the law firm Gitti and Partners as the company’s Legal Advisors for the preparation of the company’s path to listing on the Euronext Paris Stock Exchange. The firm Gitti and Partners can boast many years of experience in stock market listings. Its professionals have developed specialized expertise and operational skills in […]
